Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON-Plus open-label extension of dimebon in Huntington's disease
NL-OMON34299Phase 3Active, not recruiting
- Sponsor
- Medivation
- Start
- Sep 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of latrepirdine in Huntington disease (HD), sponsored by Medivation. Primary endpoint: Long-term safety of dimebon. Started Sep 2010; status: active, not recruiting.
02
Drugs
latrepirdine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON34299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34299.